EAU 2025 | Professors Haige Chen and Ruiyun Zhang Share Advances in Non-Invasive Bladder-Sparing Detection and Targeted-Immunotherapy Combinations
Trimodality therapy (TMT)is a well-established bladder-sparing strategy for patients with muscle-invasive bladder cancer (MIBC). However, limitations remain for patients intolerant to chemotherapy and in monitoring post-treatment recurrence. Professors Haige Chen and Ruiyun Zhang of Renji Hospital, Shanghai Jiao Tong University School of Medicine, have long focused on MIBC research. This year, nine of their studies were accepted at the EAU Congress. UroStream invited Professors Chen and Zhang to share their insights on emerging approaches, including chemotherapy-free strategies combining the domestic ADC drug RC48 with PD-1 inhibitors, the value of utDNA in non-invasive monitoring, AI-based molecular subtyping, and major takeaways from the congress.
